X0306 4 2021-04-12 0001682852 Moderna, Inc. MRNA 0001690927 Zaks Tal Zvi C/O MODERNA, INC. 200 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 1 Chief Medical Officer Common Stock 2021-04-12 4 M 0 5000 12.21 A 5000 D Common Stock 2021-04-12 4 S 0 863 137.16 D 4137 D Common Stock 2021-04-12 4 S 0 1400 138.06 D 2737 D Common Stock 2021-04-12 4 S 0 1824 139.38 D 913 D Common Stock 2021-04-12 4 S 0 413 140.22 D 500 D Common Stock 2021-04-12 4 S 0 400 141.79 D 100 D Common Stock 2021-04-12 4 S 0 100 143.09 D 0 D Stock Option (Right to Buy) 12.21 2021-04-12 4 M 0 5000 0 D 2027-10-03 Common Stock 5000 156282 D The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $136.66 to $137.64. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $137.70 to $138.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $138.86 to $139.77. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $139.94 to $140.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $141.61 to $142.26. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. 229,358 of the options will vest over 4 years (25% on the first anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 137,614 of the options will vest over 5 years (25% on the second anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 91,743 of the options will vest over 6 years (25% on the third anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). /s/ Brian Sandstrom, as Attorney-in-Fact 2021-04-13